Featuring an interview with Dr Erika Hamilton, including the following topics:
- Monitoring, mitigating and managing adverse events with antibody-drug conjugates (ADCs) for breast cancer (0:00)
- Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract
- Management protocols for adverse events associated with sacituzumab govitecan (7:49)
- García JMP et al. Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial. ASCO 2024;Abstract 1101.
- Pérez-García JM et al. Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): An open-label, single-arm, phase 2 trial. eClinicalMedicine 2025;85:103309. Abstract
- Datopotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease (10:51)
- Tarantino P et al. DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease. ASCO 2025;Abstract TPS1134.
- Sequencing ADCs in breast cancer (13:12)
- Pacholczak-Madej R et al. Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions. Biochim Biophys Acta Rev Cancer 2025;[Online ahead of print]. Abstract
CME information and select publications
